![Axel-Sven Malkomes](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Axel-Sven Malkomes
Directeur Financier/CFO chez
INVENTIVA
Profil
Axel-Sven Malkomes is currently Chief Financial Officer at Inventiva SA since 2026.
Formerly, Mr. Malkomes was Chief Financial & Business Development Officer at MediGene AG from 2019 to 2022, Vice Chairman & MD-Life Sciences Practice at Barclays PLC from 2016 to 2019, Global Head-Healthcare & Chemicals Investment at Société Générale SA from 2010 to 2016, Independent Director at Cellectis SA from 2022 to 2025, and held positions as Director at 3i Deutschland Gesellschaft für Industriebeteiligungen mbH, Managing Director at Medigene Immunotherapies GmbH, Chief Financial Officer & Managing Director at CureVac NV, Head-Strategy Planning at Merck KGaA, and Chief Financial Officer at Cardior Pharmaceuticals GmbH.
Mr. Malkomes completed undergraduate studies at the University of Bamberg.
Postes actifs de Axel-Sven Malkomes
| Sociétés | Poste | Début |
|---|---|---|
| INVENTIVA | Directeur Financier/CFO | 22/04/2026 |
Anciens postes connus de Axel-Sven Malkomes
| Sociétés | Poste | Fin |
|---|---|---|
| CELLECTIS S.A. | Directeur/Membre du Conseil | 26/06/2025 |
| MEDIGENE AG | Directeur Financier/CFO | 31/03/2022 |
| BARCLAYS PLC | Directeur/Membre du Conseil | 01/03/2019 |
| SOCIÉTÉ GÉNÉRALE | Corporate Officer/Principal | 01/01/2016 |
3i Deutschland Gesellschaft für Industriebeteiligungen mbH
 3i Deutschland Gesellschaft für Industriebeteiligungen mbH Investment ManagersFinance 3i Deutschland is an active manager which aims to invest in small and medium-sized German companies at all stages of development across a range of business sectors. The firm focuses on building partnerships with family-owned businesses, seeking to deliver profitable growth by providing local market understanding, deal experience, broad-based sector expertise and their international network. They introduce investee companies to experienced industrialists and expert advisers, offering perspectives on industry trends and helping to identify new strategies for success and value growth. For venture capital investments, 3i Deutschland invests across a range of businesses from start-ups to established innovators seeking rapid growth, supporting companies at the leading edge in healthcare technology, the consumerization of IT and cleantech. The firm invests growth capital by making minority investments in established, mid-cap, family-owned companies. Their investee businesses use the funds to restructure shareholdings and achieve growth, organically or by acquisition. 3i Deutschland invests in buyouts by acquiring majority holdings in established, mid-cap companies with outstanding management teams and excellent prospects for growth. The firm participates in MBOs, division spin-offs and supporting IPO preparations. They also invest in infrastructure assets, providing structured financing in the transport and logistics, utilities, civil engineering, medicare and public private partnerships sectors. | Private Equity Investor | 01/01/2010 |
Formation de Axel-Sven Malkomes
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
63
Relations au 1er degré
11
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 11 |
|---|---|
Merck KGaA
 Merck KGaA Pharmaceuticals: MajorHealth Technology Engages in the manufacturing of pharmaceutical and chemical products | Health Technology |
Société Générale SA
 Société Générale SA Major BanksFinance Provides retail and private banking, investment, financial advisory & insurance services | Finance |
Barclays PLC
 Barclays PLC Investment Banks/BrokersFinance Operates as a bank holding company whose subsidiaries engages in retail banking, credit cards, corporate and investment banking and wealth management services | Finance |
MediGene AG
 MediGene AG BiotechnologyHealth Technology Engages in the clinical research and development of novel drugs against cancer & autoimmune diseases with focus on personalized immunotherapies | Health Technology |
3i Deutschland Gesellschaft für Industriebeteiligungen mbH
3i Deutschland Gesellschaft für Industriebeteiligungen mbH Investment ManagersFinance 3i Deutschland is an active manager which aims to invest in small and medium-sized German companies at all stages of development across a range of business sectors. The firm focuses on building partnerships with family-owned businesses, seeking to deliver profitable growth by providing local market understanding, deal experience, broad-based sector expertise and their international network. They introduce investee companies to experienced industrialists and expert advisers, offering perspectives on industry trends and helping to identify new strategies for success and value growth. For venture capital investments, 3i Deutschland invests across a range of businesses from start-ups to established innovators seeking rapid growth, supporting companies at the leading edge in healthcare technology, the consumerization of IT and cleantech. The firm invests growth capital by making minority investments in established, mid-cap, family-owned companies. Their investee businesses use the funds to restructure shareholdings and achieve growth, organically or by acquisition. 3i Deutschland invests in buyouts by acquiring majority holdings in established, mid-cap companies with outstanding management teams and excellent prospects for growth. The firm participates in MBOs, division spin-offs and supporting IPO preparations. They also invest in infrastructure assets, providing structured financing in the transport and logistics, utilities, civil engineering, medicare and public private partnerships sectors. | Finance |
Cellectis SA
 Cellectis SA Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops immunotherapies | Health Technology |
University of Bamberg
 University of Bamberg Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Medigene Immunotherapies GmbH
 Medigene Immunotherapies GmbH Pharmaceuticals: MajorHealth Technology Develops immunotherapy to treat cancer | Health Technology |
Inventiva SA
 Inventiva SA BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops oral small molecule therapies for the treatment of MASH and other diseases | Health Technology |
Cardior Pharmaceuticals GmbH
 Cardior Pharmaceuticals GmbH Pharmaceuticals: MajorHealth Technology Engages in discovery and development of therapies that target RNA as a means to prevent, repair & reverse diseases of the hearts | Health Technology |
CureVac NV
 CureVac NV BiotechnologyHealth Technology Operates as a biopharmaceutical company that develops medicines based on messenger ribonucleic acid which includes prophylactic vaccines, oncology, and molecular therapies | Health Technology |
